ROS1-rearranged non-small cell lung carcinoma - Revision history

Michael at 20:25, 24 May 2020

2020-05-24T20:25:36Z

← Older revision		Revision as of 20:25, 24 May 2020
Line 3:		Line 3:

	==General==		==General==
	*ROS1-rearrangements are seen in approximately 1-2% of [[non-small cell carcinoma]].<ref name=pmid31720561>{{cite journal \|~~vauthors~~=Patil T, Simons E, Mushtaq R, Pacheco JM, Doebele RC, Bowles DW \|title=Targeted therapies for ROS1-rearranged non-small cell lung cancer \|journal=Drugs Today \|volume=55 \|issue=10 \|pages=641–652 \|date=October 2019 \|pmid=31720561 \|doi=10.1358/dot.2019.55.10.3030646 \|url=}}</ref>		*ROS1-rearrangements are seen in approximately 1-2% of [[non-small cell carcinoma]].<ref name=pmid31720561>{{cite journal \|authors=Patil T, Simons E, Mushtaq R, Pacheco JM, Doebele RC, Bowles DW \|title=Targeted therapies for ROS1-rearranged non-small cell lung cancer \|journal=Drugs Today \|volume=55 \|issue=10 \|pages=641–652 \|date=October 2019 \|pmid=31720561 \|doi=10.1358/dot.2019.55.10.3030646 \|url=}}</ref>
	*Respond to targeted therapy, e.g. [[crizotinib]].<ref name=pmid30980071>{{cite journal \|~~vauthors~~=Shaw AT, Riely GJ, Bang YJ, Kim DW, Camidge DR, Solomon BJ, Varella-Garcia M, Iafrate AJ, Shapiro GI, Usari T, Wang SC, Wilner KD, Clark JW, Ou SI \|title=Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001 \|journal=Ann. Oncol. \|volume=30 \|issue=7 \|pages=1121–1126 \|date=July 2019 \|pmid=30980071 \|pmc=6637370 \|doi=10.1093/annonc/mdz131 \|url=}}</ref>		*Respond to targeted therapy, e.g. [[crizotinib]].<ref name=pmid30980071>{{cite journal \|authors=Shaw AT, Riely GJ, Bang YJ, Kim DW, Camidge DR, Solomon BJ, Varella-Garcia M, Iafrate AJ, Shapiro GI, Usari T, Wang SC, Wilner KD, Clark JW, Ou SI \|title=Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001 \|journal=Ann. Oncol. \|volume=30 \|issue=7 \|pages=1121–1126 \|date=July 2019 \|pmid=30980071 \|pmc=6637370 \|doi=10.1093/annonc/mdz131 \|url=}}</ref>

	==Microscopic==		==Microscopic==
Line 13:		Line 13:

	Note:		Note:
	*Most common pattern varies by specimen type:<ref name=pmid27648828>{{cite journal \|~~vauthors~~=Zhou J, Zhao J, Zheng J, Kong M, Sun K, Wang B, Chen X, Ding W, Zhou J \|title=A Prediction Model for ROS1-Rearranged Lung Adenocarcinomas based on Histologic Features \|journal=PLoS ONE \|volume=11 \|issue=9 \|pages=e0161861 \|date=2016 \|pmid=27648828 \|pmc=5029801 \|doi=10.1371/journal.pone.0161861 \|url=}}</ref>		*Most common pattern varies by specimen type:<ref name=pmid27648828>{{cite journal \|authors=Zhou J, Zhao J, Zheng J, Kong M, Sun K, Wang B, Chen X, Ding W, Zhou J \|title=A Prediction Model for ROS1-Rearranged Lung Adenocarcinomas based on Histologic Features \|journal=PLoS ONE \|volume=11 \|issue=9 \|pages=e0161861 \|date=2016 \|pmid=27648828 \|pmc=5029801 \|doi=10.1371/journal.pone.0161861 \|url=}}</ref>
	**Biopsy specimens: solid pattern most common.		**Biopsy specimens: solid pattern most common.
	**Resection specimens: acinar pattern most common.		**Resection specimens: acinar pattern most common.
Line 40:		Line 40:

	==Molecular==		==Molecular==
	*ROS1 rearrangements can be demonstrated with dual-colour break apart [[FISH]] probes.<ref name=pmid27535289>{{cite journal \|~~vauthors~~=Bubendorf L, Büttner R, Al-Dayel F, Dietel M, Elmberger G, Kerr K, López-Ríos F, Marchetti A, Öz B, Pauwels P, Penault-Llorca F, Rossi G, Ryška A, Thunnissen E \|title=Testing for ROS1 in non-small cell lung cancer: a review with recommendations \|journal=Virchows Arch. \|volume=469 \|issue=5 \|pages=489–503 \|date=November 2016 \|pmid=27535289 \|pmc=5082594 \|doi=10.1007/s00428-016-2000-3 \|url=}}</ref>		*ROS1 rearrangements can be demonstrated with dual-colour break apart [[FISH]] probes.<ref name=pmid27535289>{{cite journal \|authors=Bubendorf L, Büttner R, Al-Dayel F, Dietel M, Elmberger G, Kerr K, López-Ríos F, Marchetti A, Öz B, Pauwels P, Penault-Llorca F, Rossi G, Ryška A, Thunnissen E \|title=Testing for ROS1 in non-small cell lung cancer: a review with recommendations \|journal=Virchows Arch. \|volume=469 \|issue=5 \|pages=489–503 \|date=November 2016 \|pmid=27535289 \|pmc=5082594 \|doi=10.1007/s00428-016-2000-3 \|url=}}</ref>

	==See also==		==See also==

Michael: /* Molecular */

2019-12-31T15:22:42Z

Molecular

← Older revision		Revision as of 15:22, 31 December 2019
Line 40:		Line 40:

	==Molecular==		==Molecular==
	*ROS1 rearrangements can be demonstrated dual-colour break apart [[FISH]] probes.<ref name=pmid27535289>{{cite journal \|vauthors=Bubendorf L, Büttner R, Al-Dayel F, Dietel M, Elmberger G, Kerr K, López-Ríos F, Marchetti A, Öz B, Pauwels P, Penault-Llorca F, Rossi G, Ryška A, Thunnissen E \|title=Testing for ROS1 in non-small cell lung cancer: a review with recommendations \|journal=Virchows Arch. \|volume=469 \|issue=5 \|pages=489–503 \|date=November 2016 \|pmid=27535289 \|pmc=5082594 \|doi=10.1007/s00428-016-2000-3 \|url=}}</ref>		*ROS1 rearrangements can be demonstrated with dual-colour break apart [[FISH]] probes.<ref name=pmid27535289>{{cite journal \|vauthors=Bubendorf L, Büttner R, Al-Dayel F, Dietel M, Elmberger G, Kerr K, López-Ríos F, Marchetti A, Öz B, Pauwels P, Penault-Llorca F, Rossi G, Ryška A, Thunnissen E \|title=Testing for ROS1 in non-small cell lung cancer: a review with recommendations \|journal=Virchows Arch. \|volume=469 \|issue=5 \|pages=489–503 \|date=November 2016 \|pmid=27535289 \|pmc=5082594 \|doi=10.1007/s00428-016-2000-3 \|url=}}</ref>

	==See also==		==See also==

Michael: /* General */

2019-12-31T15:21:59Z

General

← Older revision		Revision as of 15:21, 31 December 2019
Line 4:		Line 4:
	==General==		==General==
	*ROS1-rearrangements are seen in approximately 1-2% of [[non-small cell carcinoma]].<ref name=pmid31720561>{{cite journal \|vauthors=Patil T, Simons E, Mushtaq R, Pacheco JM, Doebele RC, Bowles DW \|title=Targeted therapies for ROS1-rearranged non-small cell lung cancer \|journal=Drugs Today \|volume=55 \|issue=10 \|pages=641–652 \|date=October 2019 \|pmid=31720561 \|doi=10.1358/dot.2019.55.10.3030646 \|url=}}</ref>		*ROS1-rearrangements are seen in approximately 1-2% of [[non-small cell carcinoma]].<ref name=pmid31720561>{{cite journal \|vauthors=Patil T, Simons E, Mushtaq R, Pacheco JM, Doebele RC, Bowles DW \|title=Targeted therapies for ROS1-rearranged non-small cell lung cancer \|journal=Drugs Today \|volume=55 \|issue=10 \|pages=641–652 \|date=October 2019 \|pmid=31720561 \|doi=10.1358/dot.2019.55.10.3030646 \|url=}}</ref>
	*Respond to ~~target~~ therapy, e.g. [[crizotinib]].<ref name=pmid30980071>{{cite journal \|vauthors=Shaw AT, Riely GJ, Bang YJ, Kim DW, Camidge DR, Solomon BJ, Varella-Garcia M, Iafrate AJ, Shapiro GI, Usari T, Wang SC, Wilner KD, Clark JW, Ou SI \|title=Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001 \|journal=Ann. Oncol. \|volume=30 \|issue=7 \|pages=1121–1126 \|date=July 2019 \|pmid=30980071 \|pmc=6637370 \|doi=10.1093/annonc/mdz131 \|url=}}</ref>		*Respond to targeted therapy, e.g. [[crizotinib]].<ref name=pmid30980071>{{cite journal \|vauthors=Shaw AT, Riely GJ, Bang YJ, Kim DW, Camidge DR, Solomon BJ, Varella-Garcia M, Iafrate AJ, Shapiro GI, Usari T, Wang SC, Wilner KD, Clark JW, Ou SI \|title=Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001 \|journal=Ann. Oncol. \|volume=30 \|issue=7 \|pages=1121–1126 \|date=July 2019 \|pmid=30980071 \|pmc=6637370 \|doi=10.1093/annonc/mdz131 \|url=}}</ref>

	==Microscopic==		==Microscopic==

Michael: /* Molecular */

2019-12-31T02:51:07Z

Molecular

← Older revision		Revision as of 02:51, 31 December 2019
Line 40:		Line 40:

	==Molecular==		==Molecular==
	*~~Testing often done with~~ dual-colour break apart FISH probes.<ref name=pmid27535289>{{cite journal \|vauthors=Bubendorf L, Büttner R, Al-Dayel F, Dietel M, Elmberger G, Kerr K, López-Ríos F, Marchetti A, Öz B, Pauwels P, Penault-Llorca F, Rossi G, Ryška A, Thunnissen E \|title=Testing for ROS1 in non-small cell lung cancer: a review with recommendations \|journal=Virchows Arch. \|volume=469 \|issue=5 \|pages=489–503 \|date=November 2016 \|pmid=27535289 \|pmc=5082594 \|doi=10.1007/s00428-016-2000-3 \|url=}}</ref>		*ROS1 rearrangements can be demonstrated dual-colour break apart [[FISH]] probes.<ref name=pmid27535289>{{cite journal \|vauthors=Bubendorf L, Büttner R, Al-Dayel F, Dietel M, Elmberger G, Kerr K, López-Ríos F, Marchetti A, Öz B, Pauwels P, Penault-Llorca F, Rossi G, Ryška A, Thunnissen E \|title=Testing for ROS1 in non-small cell lung cancer: a review with recommendations \|journal=Virchows Arch. \|volume=469 \|issue=5 \|pages=489–503 \|date=November 2016 \|pmid=27535289 \|pmc=5082594 \|doi=10.1007/s00428-016-2000-3 \|url=}}</ref>

	==See also==		==See also==

Michael: +ISH

2019-12-31T02:49:05Z

+ISH

← Older revision		Revision as of 02:49, 31 December 2019
Line 38:		Line 38:
	Image: Adenocarcinoma - ROS1 positive - ROS1 -- high mag.jpg \| NSmCC - ROS1 -high mag.		Image: Adenocarcinoma - ROS1 positive - ROS1 -- high mag.jpg \| NSmCC - ROS1 -high mag.
	</gallery>		</gallery>

			==Molecular==
			*Testing often done with dual-colour break apart FISH probes.<ref name=pmid27535289>{{cite journal \|vauthors=Bubendorf L, Büttner R, Al-Dayel F, Dietel M, Elmberger G, Kerr K, López-Ríos F, Marchetti A, Öz B, Pauwels P, Penault-Llorca F, Rossi G, Ryška A, Thunnissen E \|title=Testing for ROS1 in non-small cell lung cancer: a review with recommendations \|journal=Virchows Arch. \|volume=469 \|issue=5 \|pages=489–503 \|date=November 2016 \|pmid=27535289 \|pmc=5082594 \|doi=10.1007/s00428-016-2000-3 \|url=}}</ref>

	==See also==		==See also==

Michael at 02:42, 31 December 2019

2019-12-31T02:42:15Z

← Older revision		Revision as of 02:42, 31 December 2019
Line 1:		Line 1:
			[[Image:Adenocarcinoma_-_ROS1_positive_-_ROS1_--_high_mag.jpg\|thumb\|right\|[[Micrograph]] showing a ROS1-positive [[adenocarcinoma of the lung]]. ROS1 [[immunostain]].]]
	'''ROS1-rearranged non-small cell lung carcinoma''' is a subtype of [[non-small cell lung carcinoma]] that can be treated with [[ALK inhibitors]].<ref name=pmid25264305>{{Cite journal \| last1 = Shaw \| first1 = AT. \| last2 = Ou \| first2 = SH. \| last3 = Bang \| first3 = YJ. \| last4 = Camidge \| first4 = DR. \| last5 = Solomon \| first5 = BJ. \| last6 = Salgia \| first6 = R. \| last7 = Riely \| first7 = GJ. \| last8 = Varella-Garcia \| first8 = M. \| last9 = Shapiro \| first9 = GI. \| title = Crizotinib in ROS1-rearranged non-small-cell lung cancer. \| journal = N Engl J Med \| volume = 371 \| issue = 21 \| pages = 1963-71 \| month = Nov \| year = 2014 \| doi = 10.1056/NEJMoa1406766 \| PMID = 25264305 }}</ref>		'''ROS1-rearranged non-small cell lung carcinoma''' is a subtype of [[non-small cell lung carcinoma]] that can be treated with [[ALK inhibitors]].<ref name=pmid25264305>{{Cite journal \| last1 = Shaw \| first1 = AT. \| last2 = Ou \| first2 = SH. \| last3 = Bang \| first3 = YJ. \| last4 = Camidge \| first4 = DR. \| last5 = Solomon \| first5 = BJ. \| last6 = Salgia \| first6 = R. \| last7 = Riely \| first7 = GJ. \| last8 = Varella-Garcia \| first8 = M. \| last9 = Shapiro \| first9 = GI. \| title = Crizotinib in ROS1-rearranged non-small-cell lung cancer. \| journal = N Engl J Med \| volume = 371 \| issue = 21 \| pages = 1963-71 \| month = Nov \| year = 2014 \| doi = 10.1056/NEJMoa1406766 \| PMID = 25264305 }}</ref>

Line 36:		Line 37:
	Image: Adenocarcinoma - ROS1 positive - ROS1 -- intermed mag.jpg \| NSmCC - ROS1 - intermed. mag.		Image: Adenocarcinoma - ROS1 positive - ROS1 -- intermed mag.jpg \| NSmCC - ROS1 - intermed. mag.
	Image: Adenocarcinoma - ROS1 positive - ROS1 -- high mag.jpg \| NSmCC - ROS1 -high mag.		Image: Adenocarcinoma - ROS1 positive - ROS1 -- high mag.jpg \| NSmCC - ROS1 -high mag.
	~~Image: Adenocarcinoma - ROS1 positive - ROS1 -- very high mag.jpg \| NSmCC - ROS1 -very high mag.~~
	</gallery>		</gallery>

Michael: /* Microscopic */

2019-12-31T02:39:52Z

Microscopic

← Older revision		Revision as of 02:39, 31 December 2019
Line 8:		Line 8:
	Features:		Features:
	*Histology not definitive; however, predictive features are:<ref name=pmid27648828/>		*Histology not definitive; however, predictive features are:<ref name=pmid27648828/>
	**Cribriform structure.		**[[Cribriform structure]].
	**[[Psammoma bodies]]		**[[Psammoma bodies]]

Michael: /* References */

2019-12-31T02:38:21Z

References

← Older revision		Revision as of 02:38, 31 December 2019
Line 45:		Line 45:

	==References==		==References==
	{{Reflist\|1}}		{{Reflist\|2}}

	[[Category:Diagnosis]]		[[Category:Diagnosis]]
	[[Category:Molecular pathology]]		[[Category:Molecular pathology]]

Michael: /* References */

2019-12-31T02:31:28Z

References

← Older revision		Revision as of 02:31, 31 December 2019
Line 48:		Line 48:

	[[Category:Diagnosis]]		[[Category:Diagnosis]]
			[[Category:Molecular pathology]]

Michael at 02:30, 31 December 2019

2019-12-31T02:30:28Z

← Older revision		Revision as of 02:30, 31 December 2019
Line 16:		Line 16:
	**Resection specimens: acinar pattern most common.		**Resection specimens: acinar pattern most common.

	==Images==		===Images===
	~~==Related images~~==
	<gallery>		<gallery>
	Image: Adenocarcinoma - ROS1 positive -- low mag.jpg \| NSmCC - low mag.		Image: Adenocarcinoma - ROS1 positive -- low mag.jpg \| NSmCC - low mag.
Line 24:		Line 23:
	Image: Adenocarcinoma - ROS1 positive -- very high mag.jpg \| NSmCC - very high mag.		Image: Adenocarcinoma - ROS1 positive -- very high mag.jpg \| NSmCC - very high mag.

			Image: Adenocarcinoma - ROS1 positive - TTF1 -- high mag.jpg \| NSmCC - TTF-1 - high mag.

			Image: Adenocarcinoma - ROS1 positive - napsin A -- high mag.jpg \| NSmCC - napsin A - high mag.
			</gallery>

			==IHC==
			*ROS1 +ve.

			===Images===
			<gallery>
	Image: Adenocarcinoma - ROS1 positive - ROS1 -- low mag.jpg \| NSmCC - ROS1 - low mag.		Image: Adenocarcinoma - ROS1 positive - ROS1 -- low mag.jpg \| NSmCC - ROS1 - low mag.
	Image: Adenocarcinoma - ROS1 positive - ROS1 -- intermed mag.jpg \| NSmCC - ROS1 - intermed. mag.		Image: Adenocarcinoma - ROS1 positive - ROS1 -- intermed mag.jpg \| NSmCC - ROS1 - intermed. mag.
	Image: Adenocarcinoma - ROS1 positive - ROS1 -- high mag.jpg \| NSmCC - ROS1 -high mag.		Image: Adenocarcinoma - ROS1 positive - ROS1 -- high mag.jpg \| NSmCC - ROS1 -high mag.
	Image: Adenocarcinoma - ROS1 positive - ROS1 -- very high mag.jpg \| NSmCC - ROS1 -very high mag.		Image: Adenocarcinoma - ROS1 positive - ROS1 -- very high mag.jpg \| NSmCC - ROS1 -very high mag.

	~~Image: Adenocarcinoma - ROS1 positive - TTF1 -- high mag.jpg \| NSmCC - TTF-1 - high mag.~~

	~~Image: Adenocarcinoma - ROS1 positive - napsin A -- high mag.jpg \| NSmCC - napsin A - high mag.~~
	</gallery>		</gallery>